financetom
Business
financetom
/
Business
/
India's Infosys accuses rival Cognizant of anti-competitive practices
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
India's Infosys accuses rival Cognizant of anti-competitive practices
Jan 10, 2025 6:14 AM

BENGALURU, Jan 10 (Reuters) - India's Infosys

filed a counterclaim against rival Cognizant in a Texas

federal court on Thursday, accusing the U.S.-based firm of

engaging in anti-competitive practices and poaching key

executives.

India's second-largest software company accused Cognizant of

anti-competitive practices such as including clauses in

contracts that stop clients from awarding IT services work to

competitors and refusing them training on its software.

The Bengaluru-based company also said Cognizant indulged in

targeted recruitment of key senior executives, including

appointing S Ravi Kumar as its CEO in 2023, that delayed its

ability to develop a competing software product called Infosys

Helix.

Infosys and Cognizant did not immediately respond to

Reuters' requests for comments.

The counterclaim comes after Cognizant subsidiary TriZetto

(AXPAST.UL) sued Infosys last August, accusing the Indian tech

major of stealing trade secrets related to its healthcare

insurance software.

TriZetto's Facets and QNXT are used by healthcare insurance

companies to automate administrative tasks.

In its complaint the Teaneck, New Jersey-based company said

Infosys misused TriZetto's software to create "Test Cases for

Facets," which improperly repackaged TriZetto's data into an

Infosys product.

Infosys has sought three times its damages suffered as well

as the awarding of attorney fees and costs related to the case.

The quantum of damages was not disclosed in the filing.

The case is Cognizant TriZetto Software Group Inc v. Infosys

Ltd, U.S. District Court for the Northern District of Texas, No.

3:24-cv-02158-X.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lululemon Q1 Earnings: Revenue Beat, EPS In Line, Shares Tumble On Weaker Earnings Forecast
Lululemon Q1 Earnings: Revenue Beat, EPS In Line, Shares Tumble On Weaker Earnings Forecast
Jun 5, 2025
Lululemon Athletica Inc ( LULU ) reported first-quarter financial results Thursday after the market close. Here’s a look at the key details from the quarter. Q1 Earnings: Lululemon reported first-quarter revenue of $2.37 billion, beating the consensus estimate of $2.36 billion, according to Benzinga Pro. Total revenue was up 7% on a year-over-year basis as Americas net revenue increased 3% and international...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
BRIEF-GlycoMimetics Stockholders Approve Proposed Merger With Crescent Biopharma And All Related Proposals
BRIEF-GlycoMimetics Stockholders Approve Proposed Merger With Crescent Biopharma And All Related Proposals
Jun 5, 2025
June 5 (Reuters) - GlycoMimetics Inc ( GLYC ): * GLYCOMIMETICS STOCKHOLDERS APPROVE PROPOSED MERGER WITH CRESCENT BIOPHARMA AND ALL RELATED PROPOSALS * GLYCOMIMETICS INC ( GLYC ) - BOARD APPROVES 1-FOR-100 REVERSE STOCK SPLIT * GLYCOMIMETICS INC ( GLYC ) - REVERSE STOCK SPLIT TO REDUCE OUTSTANDING SHARES TO 0.6 MILLION Source text: Further company coverage: ...
Blueprint Medicines Insider Sold Shares Worth $340,033, According to a Recent SEC Filing
Blueprint Medicines Insider Sold Shares Worth $340,033, According to a Recent SEC Filing
Jun 5, 2025
04:30 PM EDT, 06/05/2025 (MT Newswires) -- Percy H. Carter, Chief Scientific Officer, on June 03, 2025, sold 2,659 shares in Blueprint Medicines ( BPMC ) for $340,033. Following the Form 4 filing with the SEC, Carter has control over a total of 54,206 common shares of the company, with 54,206 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1597264/000141588925015767/xslF345X05/form4-06052025_040601.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved